14:00 CET

Oncopeptides Virtual Capital Markets Day

The Program

14.00 – 16.00 CET (8:00am-10am EST) November 30th, 2020

 

“Building a Fully Integrated Biotechnology Company”

  • Introduction and Strategy for Value Growth – Marty J Duvall, CEO Oncopeptides
  • Multiple Myeloma
    “Myeloma remains one of the largest unmet medical needs within hematology”
    o Assistant Professor Joshua Richter, MD. Icahn School of Medicine at Mount Sinai Hospital, New York
  • Relapsed refractory multiple myeloma and melflufen – clinical experience with melflufen – Panel discussion
    o Professor Paul Richardson, MD, Dana-Farber Cancer Institute, Boston
    o Associate Professor Maria-Victoria Mateos, MD, PhD, University Hospital, Salamanca
    Moderated by Klaas Bakker, MD, PhD, CMO Oncopeptides
  • The clinical development program for melflufen
    “Understanding how melflufen can help patients the most” – Jakob Lindberg, CSO Oncopeptides
  • Successfully making the drug available for patients in the US
    Overview of US launch of melflufen – Marty J Duvall, CEO Oncopeptides
  • Questions and Answers

 

The CMD will be webcasted live on the link:https://tv.streamfabriken.com/oncopeptides-cmd-2020

Upcoming events

Silent Period

-

FDA - Oncologic Drugs Advisory Committee (ODAC) Meeting

The US Food and Drug Administration, FDA, has announced a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (ODAC), on October 28, 2021 concerning Oncopeptides’ product Pepaxto. The information is in line with the FDA safety alert on July 28, where the FDA stated that a public meeting may be hold to discuss the safety findings from the OCEAN study.

Interim Report Q3 2021

08:00 CET

63rd ASH Annual Meeting & Exposition

-

American Society of Hematology (ASH) 63rd annual meeting with both in-person and virtual participation at the Georgia World Congress Center in Atlanta, Georgia. ASH Annual Meeting & Exposition is the largest event in malignant and non-malignant hematology.

Silent Period

-

Year-end report 2021

08:00 CET

Silent Period

-

Silent Period

-